Monday, July 18, 1994
The capital market and health care environments are putting a premium on the ability of biotech companies to rethink their business strategies to fit the times. Except for a lucky few, companies of the class of '91-92 that grew up with the fully integrated biopharmaceutical company (Fibco) model risk being left behind.
One company that isn't waiting is Glycomed Inc., which on Friday announced that it has restructured its business to focus on the discovery and development of small molecule drugs - becoming a fully integrated drug discovery organization, or Fiddo. (See below.)